Opinion|Videos|July 13, 2024
Highlights from ASCO 2024: Individualized Neoantigen Therapy in Melanoma
Considerations for neoantigen therapy tailored to specific patient needs is discussed by Dr Lipson.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Discuss the 3-year updated data presented at ASCO 2024 on individualized neoantigen therapy (mRNA-4157) plus pembrolizumab in resected melanoma.
- What was the objective of this study?
- How was this study designed/what methodology was used?
- What results were presented?
- Please provide your key takeaways from this study. How might these findings impact the management of patients with melanoma?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Novel CLL Therapies Prompt New Treatment Considerations
2
Congress Unveils Massive Funding Bill to Avert Shutdown
3
Anlotinib Plus Chemotherapy Shows Promising Results in Advanced Soft Tissue Sarcoma
4
Early Data Show Feasibility of in Vivo CAR T Therapy in Multiple Myeloma
5
